MannKind at Morgan Stanley Healthcare Conference (Replay)
09/09/14 at 12:55 p.m. ET
MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
|09/02/14||MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference|
|VALENCIA, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at 12:55 PM (ET) at the Grand Hyatt Hotel in New York City.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at ht... |
|08/11/14||Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin|
|Paris and Valencia, Calif. - August 11, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015.
Under the collabo... |
|08/11/14||MannKind Corporation Reports 2014 Second Quarter Financial Results|
|VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2014.
For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the second quarter of 2013, an increase of $28.2 million, largely due to an increase in non-cash stock compensation expense of $30.5 million. In the second quarter of 2014, the settlement terms for certain performance-based a... |
|08/05/14||MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014|
|VALENCIA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 second quarter financial results on Monday, August 11, 2014 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM (Eastern Time) on August 11, 2014.
Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Officer, Hakan Edstrom, and Corpora... |